01 — At a Glance
The Plastic Film King Nobody’s Watching (Because Why Would You?)
- 52-Week High / Low₹1,398 / ₹774
- Q3 FY26 Revenue₹1,682 Cr
- Q3 FY26 PAT₹30 Cr (Before Minority)
- TTM EPS₹9.64
- Annualised EPS (Q3 Avg × 4)₹18.8
- Book Value / Share₹1,287
- Price to Book0.66x
- Gross NPA (Dec 2025)N/A (Manufacturing)
- Current Ratio2.79x
- Total Assets (Sep 2025)₹8,616 Cr
Flash Summary: Polyplex just delivered Q3 FY26 PAT of ₹30 crore (standalone ₹14.8 crore consolidated before minority)—down 74.4% quarter-on-quarter, and down 27% year-on-year. The stock is down 24% in a year at ₹853. Profit margin has collapsed from 28% to negative. The company is trading at 0.66x book value. Somewhere in Mumbai, a PE fund is regretting its AGP Holdco deal. Somewhere in Noida, Polyplex’s CEO is sweating profusely.
02 — Introduction
The Unsung Hero of Your Snacks Bag (And Why It’s Drowning)
Let’s set the stage. Every time you tear open a Lay’s packet with your pinky finger—you know, that precise moment of primal satisfaction—you’re touching plastic film made by Polyplex. Same with your medicine bottles, your frozen food packets, and that shrink-wrap on your Amazon parcel. Polyplex has been making plastic films since 1984. They are ranked #2 globally (excluding China) in thin BOPET film capacity.
But here’s the problem: plastic films are a commodity. When crude oil prices fall, raw material costs fall. When raw material costs fall, selling prices fall faster. When selling prices fall faster than costs, margins disappear. And when margins disappear, managements start telling very creative stories to analysts on earnings calls.
Q3 FY26 tells the story of a company caught in an oversupplied industry, wrestling with reciprocal tariffs on US exports, currency headwinds, and high fixed costs. Revenue is barely growing at 1.91% (5-year), but profit has gone on a three-year negative vacation averaging -3.71% decline. The company is investing heavily in new capacity—a BOPET line in Bazpur, metallizers, coaters—betting that specialty films (D-PAC products) will rescue margins. The new US facility is ramping up. Management is optimistic. But the balance sheet? It’s screaming for a profit recovery, and the profit is taking its sweet time.
Analyst Note from Q3 Concall (Feb 2026): Management blamed “reciprocal tariffs on US exports, uncertainty around trade policy, and a slower-than-anticipated ramp-up of the US facility.” They also mentioned “oversupply in BOPP and BOPET markets since 1H FY23.” Translation: “The industry is broken, tariffs are hurting us, and we’re not making money yet. Please have faith in our new investments.”
03 — Business Model: We Make Plastic. We Sell It. We Hope Margins Exist.
A Vertically Integrated Plastic Film Manufacturer That’s Playing the Long Game (And Losing).
Polyplex makes BOPET films (biaxially oriented polyethylene terephthalate—say that three times fast). They also make BOPP, CPP, and blown films. The products go into flexible packaging (69% of revenue in FY23), and industrial applications (31%). Food companies use it. Pharma uses it. Printing companies use it. Converters use it. Everyone uses it. But nobody cares about the margin.
The company is backward-integrated. They have PET resin plants at every manufacturing location. Forward-integrated too—metallizing, silicone coating, holography. This is supposed to reduce costs and increase value addition. But when the industry is in oversupply, integration doesn’t save you. It just means you’re losing money at multiple levels.
They have 7 manufacturing facilities across 5 countries: India, Thailand, Turkey, USA, and Indonesia. They serve 2,735 customers in 86 countries. Geographic diversification is their shield against regional demand shocks. But tariffs? Tariffs don’t care about diversification. They just hit hard and fast.
Thin BOPET53%of revenue (9MFY26)
Downstream16%coated, metallized
BOPP Films14%of revenue
PET Resin7%of revenue
Fun fact from the concall: The company’s capacity utilization in Thin BOPET is still a respectable 89% (YTD Q3 FY26 annualized), but the industry average is only 59%. So Polyplex is actually running hotter than peers. Problem is—when the entire industry is oversupplied, even 89% utilization doesn’t guarantee profits. It just means you’re losing money at scale.
04 — Financials Overview
Q3 FY26: The Numbers Make You Cry
Result type: Quarterly Results | Q3 FY26 EPS: ₹4.70 | Avg Q1–Q3 EPS: (₹12.32+₹2.42+₹4.70)/3 = ₹6.48 | Annualised EPS: ₹25.92 (but it feels wrong to annualize this)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,682 | 1,721 | 1,739 | -2.25% | -3.28% |
| Operating Profit | 105 | 121 | 103 | -13.2% | +1.9% |
| OPM % | 6% | 7% | 6% | -100 bps | flat |
| PAT | 30 | 41 | 34 | -27% | -12% |
| EPS (₹) | 4.70 | 6.42 | 7.87 | -26.9% | -40.3% |
Real Talk: This quarter is depressing. Revenues are down 2% YoY. Profits are down 27% YoY. EPS is down 27% YoY. The company is making 6% operating margin when it should be making 10%+. The normalized EBITDA (excluding FX impacts) for Q3 was 7% margin—still weak for a company that made 20% EBITDA margins back in FY22. The concall mentioned “softer demand in industrial films segment and seasonality impact” and “market sentiment remained cautious.” Translation: The whole industry is depressed, and Polyplex caught the flu harder than others.
💬 Can a company trading at 0.66x book with only 5.72% ROE actually generate the returns needed to justify a turnaround narrative? Or is this a value trap wrapped in specialty film promises? What do you think?
05 — Valuation Discussion: Fair Value Range
What Is This Film Manufacturer Actually Worth?
Method 1: P/E Based Valuation
TTM EPS = ₹9.64. Industry median P/E for packaging companies = 16.88x. A reasonable P/E for a cyclical film company in trough profitability: 9x–12x. Let’s use 10x–12x as the fair valuation band, assuming a recovery is underway.
→ 10x × ₹9.64 = ₹96.4 12x × ₹9.64 = ₹115.68
Range: ₹96 – ₹116
Method 2: Price to Book Value
Book Value = ₹1,287. Current P/BV = 0.66x (trading below book, which is unusual for a healthy manufacturer). For a cyclical business in trough, 0.7x–0.9x book is fair. For normalized times, 1.0x–1.2x is reasonable.
→ 0.8x × ₹1,287 = ₹1,030 1.0x × ₹1,287 = ₹1,287
Range: ₹1,030 – ₹1,287
Method 3: EV/EBITDA (Normalized Basis)
TTM Normalized EBITDA = ~₹400 Cr (after adjusting for unrealized FX losses). EV (at ₹853 CMP, Market Cap ₹2,676 Cr, Net Debt ~₹-1,200 Cr) = ~₹1,476 Cr (negative net debt means cash is in excess). EV/EBITDA = 3.7x. Given the cycle, 4x–6x is reasonable for normalized earnings.
At 4.5x–5.5x normalized EBITDA, equity value per share is ₹900–₹1,050 range.
Range: ₹900 – ₹1,050
Consolidated View: The three methods suggest a fair value range of ₹900–₹1,287 on a normalized earnings basis. The current price of ₹853 is in the lower-to-middle of this range, reflecting the market’s skepticism about the profitability recovery. The stock is not expensive by P/B metrics, but the low ROE (5.72%) and negative profit trend make this a value trap, not a value opportunity—unless the company can prove that specialty films (D-PAC) and the new US facility will deliver a meaningful margin recovery in the next 2-3 quarters.
⚠️ EduInvesting Fair Value Range: ₹900 – ₹1,050. This fair value range is for educational purposes only and is not investment advice. Cyclical companies in trough profitability carry execution risk. Please consult a SEBI-registered investment advisor before making any financial decision.
06 — What’s Cooking: Tariffs, Arbitration & Management Drama
The Plot Thickens. And It’s Not Pretty.
